Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Denali gains on Parkinson’s results as it looks to select a Phase II candidate

Hongjiang Li, Staff Writer
January 15, 2020 12:18 AM UTC

Denali reported data Tuesday from pair of Phase I trials that will inform the company’s selection of a Parkinson’s disease candidate to advance to Phase II.

Denali Therapeutics Inc. (NASDAQ:DNLI) gained $5.16 (29%) to $22.74 after presenting safety and biomarker data for its two small molecule LRRK2 inhibitors for PD at the J.P. Morgan Healthcare Conference in San Francisco. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Denali Therapeutics Inc.